Skip to Main Content

At Verily, a growing line of business builds on a revolving door to the FDA

Verily wants to build the technology that will run the next generation of clinical trials — and it is filling its ranks with FDA experts to do that.

How can the latest Alzheimer’s therapy reach patients? Follow this trustworthy process

If the lecanemab data hold up to scrutiny, it sounds like an Alzheimer's drug I might prescribe. Or maybe not.

Harassment prompts children’s hospitals to strip websites, threatening access to gender-affirming care

Children’s hospitals, facing harassment online, are stripping their websites of information about gender-affirming care. Doctors and advocates are concerned the changes will make it harder for patients to get care they need.

Maternal-fetal surgery is not an alternative to abortion care

Maternal-fetal surgery can never replace the option for abortion. To suggest otherwise is inaccurate, dangerous, and insensitive to those carrying a baby diagnosed with a severe fetal condition.

Who will get the call from Stockholm? It’s time for STAT’s 2022 Nobel Prize predictions

The shortlist of possible Nobel Prize winners this year in science and medicine includes researchers who elucidated how cells make energy and discovered the chemical chatter of bacteria, and the pioneers behind Covid mRNA vaccines.

How health systems can truly value Black lives: help close the racial wealth gap

Health systems are uniquely positioned to address the racial wealth gap because they are often economic engines in their communities with both job opportunities and purchasing power.

Researchers show they can quickly turn CAR-T cells on and off, raising hopes for safer cancer treatments

"Switchable" CAR-T cells could be quickly and reliably turned on and off in cancer patients, giving scientists unprecedented control over this sometimes-dangerous therapy.

Advances in treating the sickest Covid patients have stalled. Why?

Advances in treating the sickest Covid patients have stalled, even as more than 2,000 patients continue to die daily around the globe. 

‘This is pharma’s dream’: How drugmakers are turning telehealth into a marketing gold mine

For pharma companies, online prescribing has now become a powerful tool to drive sales, sending hundreds of thousands of patients to the clinic at the moment they’re most primed to ask for a specific prescription.

How a tool to map computer viruses came to power biology research

Two mathematicians set out to map computer viruses and spot the differences. The result is a tool that's become surprisingly valuable in biology research.

Moderna sues Pfizer and BioNTech over Covid-19 vaccine

Moderna on Friday sued Pfizer and BioNTech, its main rivals in the mRNA Covid vaccine race, for allegedly infringing on its patents.

What Fauci’s exit tells us about the ongoing fight against Covid

There was a time when Anthony Fauci thought he would retire when the Covid-19 pandemic was over. That, he admits now, may never happen. But this December, he announced this week, will have to be good enough.

The FDA is at a crossroads for reducing tobacco-related disease and death

Congress must keep building upon the progress it has made to provide the FDA with explicit authority to regulate e-cigarettes and other products associated with tobacco-related harm.

How a long-overlooked protein could remake neuroscience drug discovery — or plunge the FDA into controversy

In a blood sample, the protein neurofilament is like the presence of rubble in a river — a sign of destruction upstream.

‘A poster child’ for diversity in science: Black engineers work to fix long-ignored bias in oxygen readings

The fact that Black engineers are leading the charge to fix the long-ignored disparity with pulse oximeters is a clear example of what’s lost when most scientists are white.

As the Smithsonian wraps a landmark genome exhibit, leaders in the field reflect on what’s changed

The Smithsonian will soon wrap a genomics exhibit that first opened nearly a decade ago. STAT spoke to George Church, Joann Boughman, Eric Green, and other experts in the field about what's changed since.

‘Is an abortion medically necessary?’ is not a question for ethicists to answer

Involving hospital ethics committees in decisions about the medical necessity of abortion is misguided and dangerous. Ethics committees should refuse to take part deciding if a recommended abortion is legally permissible.

At pioneering center for gene therapy, Jim Wilson presided over toxic, abusive workplace, staffers say

At pioneering center for gene therapy, researcher Jim Wilson presided over a toxic, abusive workplace, according to current and former staffers.

New data might have led to a different result for Amarin fish oil drug, FDA panelists say

Two members of an expert panel that recommended the FDA approve a fish-oil-based heart drug, Vascepa, said recently released data would have led them to reconsider their votes.

Rare Disease Research: A Prescription

Research into rare disease has led to new treatments and some breakthroughs. But are the policies and science aligned to produce treatments? We'll speak with the lawmakers and patient advocates working to create this alignment. STAT+ subscribers unlock a free ticket when the check out with their subscriber credentials! AGENDA 6:00 - 6:30 PM ET…

Secrecy: A demon of gene therapy’s past bedevils its future

Transparency in gene therapy research is vital to success. One high-profile failure would badly hurt the revival of gene therapy; two would send it back into hibernation.

Common injections don’t help knee osteoarthritis more than placebo, large data review finds

Despite decades of mounting evidence showing hyaluronic acid injections don’t help most osteoarthritis patients, the shots have become more widely used.

The 41 best books and podcasts on health and science to check out this summer

The STAT summer book/podcast list is back: Check out recommendations from @michaelpollan, @doctorsoumya, @mclemoremr, @drpennyheaton, STAT readers and staff, and more!

Beyond a CRISPR treatment’s encouraging results, some scientists see a need for more data on risk

What happens when you CRISPR people? Some scientists say, despite encouraging results so far, the answer is incomplete.

To protect people with addiction from discrimination, the Justice Dept. turns to a long-overlooked tool: the ADA

“This kind of discrimination is overt,” Gregory Dorchak, an assistant U.S. attorney in Massachusetts who has led many of these investigations, said on a recent webinar.

Reformulating drugs helps profits more than patients

Enabling access to prescription drugs and encouraging clinically meaningful pharmaceutical innovation should go hand in hand, and not be in such direct tension.

Enhertu, a smart bomb drug, dramatically extends survival in breast cancer patients

The cancer drug Enhertu cut the rate of death in a group of women with advanced breast cancer by a third in a new clinical trial, a result that oncologists said could shift the way they think about treating the disease.

Monkeypox is recapitulating the stigma and structural inequity of HIV, Ebola, and other diseases

Pathogens don't discriminate like humans do — they have no innate capability of discerning race, sexual orientation, religion, or nationality. But they can hijack structural inequities embedded within societies.

Coronavirus hasn’t developed resistance to Paxlovid. How long can that last?

“At some point, there will be Paxlovid-resistant virus," said Adam Lauring, who studies RNA virus evolution at the University of Michigan. "Whether that clinically becomes a problem or not, it’s hard to say.”